Case report
Open access
Jul 2026
Case Report: When access is limited: using CYP3A4 inhibition to maintain clinical benefit from elexacaftor/tezacaftor/ivacaftor
The potential for CYP3A4 inhibition to aid with personalised ETI dosing strategies is supported, particularly in low and middle-income countries where CFTRm access remains limited.
Keirran Hiscock, Michelle Wood, Ellie Johnson et al.
· Frontiers in Pharmacology · 0 citations